IPP Bureau
Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr
By IPP Bureau - August 10, 2022
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
By IPP Bureau - August 09, 2022
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr
By IPP Bureau - August 09, 2022
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
Briefs: Zydus Lifesciences and Kimia Biosciences
By IPP Bureau - August 09, 2022
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Lyka Labs swings back to profit in Q1FY23
By IPP Bureau - August 09, 2022
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
By IPP Bureau - August 09, 2022
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad
By IPP Bureau - August 09, 2022
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
JB Pharma records revenue growth of 30% in Q1 FY23
By IPP Bureau - August 09, 2022
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
By IPP Bureau - August 09, 2022
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer
By IPP Bureau - August 09, 2022
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Ube to buy API Corp. from Mitsubishi Chemical
By IPP Bureau - August 09, 2022
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
L&T donates a bus to Sankara Eye Hospital for their outreach programme
By IPP Bureau - August 08, 2022
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
Biocon Sdn. Bhd. enters Malaysia Book of Records
By IPP Bureau - August 08, 2022
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
FDC Limited reports Q1 FY23 revenue growth of 10%
By IPP Bureau - August 08, 2022
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Valiant Organics to start production of OAP and Pharma Intermediates
By IPP Bureau - August 08, 2022
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
